A Phase 2 clinical trial will test BMND08, an investigational oral therapy based on a natural psychedelic, in treating depression and…
Articles by Patricia Inacio, PhD
Alzamend Neuro has dosed the first patient in the multiple ascending dose portion of its Phase 2a clinical trial…
Eisai has completed a rolling submission to the U.S. Food and Drug Administration (FDA) to seek approval for lecanemab…
A U.S. Food and Drug Administration (FDA) advisory committee will host a virtual meeting to review a request to expand the…
A Miami Veterans Affairs (VA) clinical site is now part of Longeveron’s Phase 2a clinical trial testing…
A first patient has been dosed in a Phase 2 trial of XPro1595, INmune Bio’s candidate therapy…
Gain Therapeutics‘ investigational STAR (small-molecule structurally targeted allosteric regulators) candidate lowered toxic amyloid-beta and tau protein levels, both hallmarks…
Alzamend Neuro’s experimental oral therapy for dementia related to Alzheimer’s disease may deliver the benefits of marketed lithium-based…
Biogen, the co-developer of Aduhelm (aducanumab) has submitted the final protocol for ENVISION — the Phase 4…
Prothena has begun testing single ascending doses (SAD) of PRX012, its investigational anti-amyloid beta antibody therapy, in a Phase…